YANTAI, China, June 2, 2025 /PRNewswire/ -- On June 2 (Chicago time), in an oral presentation at the 2025 ASCO Annual Meeting, Dr. Lin Shen from Beijing Cancer Hospital presented the results of a ...
In patients with clear cell renal cell carcinoma (ccRCC), there are a number of second-line options to consider. Sumanta K. Pal, MD, FASCO, professor, Department of Medical Oncology & Therapeutics ...
Transitioning from IV to Sub-Q Darzalex Faspro significantly improved Kennedy's quality of life, reducing treatment time and enhancing productivity. The FDA approved Darzalex Faspro for high-risk ...
In the age of targeted therapy, what’s the best long-term strategy to treat chronic lymphocytic leukemia (CLL), the most common leukemia in Western countries? Should treatment be continuous to achieve ...
Ianalumab combined with eltrombopag significantly extends time to treatment failure and improves stable response rates in ITP patients relapsing after first-line steroids. The combination therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results